[144] IONIS PHARMACEUTICALS INC SEC Filing

Rhea-AI Filing Summary

Form 144 filing by Ionis Pharmaceuticals (IONS) reports a proposed sale of 49,800 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $3,249,734.00. The shares are listed on Nasdaq and the filing lists 159,391,229 shares outstanding for the issuer. The securities were acquired on 01/02/2019 by option exercise from the issuer and the intended sale is scheduled for 09/30/2025 with payment in cash. The filer reports no sales in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale notice: 49,800 shares, $3.25M value, scheduled 09/30/2025.

This Form 144 documents a planned sale under Rule 144 by a person who acquired the shares via option exercise on 01/02/2019. The sale is to be executed through Stifel Nicolaus & Company on Nasdaq with cash payment. The filing indicates no securities sold by this person in the prior three months and reiterates the signer’s representation about lack of undisclosed material adverse information. The notice is procedural and provides transaction timing and dealer details required for compliance.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; standard attestation and broker details included.

The filing includes required issuer and transaction details: class of securities, broker name and address, number of shares, aggregate value, outstanding shares figure, acquisition date and nature (option exercise), and intended sale date. It contains the customary signature attestation about material information and a warning regarding false statements. No additional governance actions or plan-adoption dates (e.g., 10b5-1) are disclosed in the form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	49800	3249734.00	159391229	09/30/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/02/2019	Option Exercise	Issuer			49800	09/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 49,800 shares of common stock through Stifel Nicolaus & Company, with aggregate market value $3,249,734.00, intended sale date 09/30/2025.

How and when were the shares acquired according to the filing?

The shares were acquired on 01/02/2019 by option exercise from the issuer; the filing lists cash as the nature of payment on sale.

Does the filer report any sales of Ionis stock in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

On which exchange will the proposed sale take place?

The filing indicates the securities exchange as Nasdaq.

What outstanding share count does the filing report for the issuer?

The filing lists 159,391,229 shares outstanding for the issuer.